Discuss the role of the National Pharmaceutical Pricing Authority in ensuring affordable access to essential medicines. What are its limitations?

The National Pharmaceutical Pricing Authority (NPPA), an executive body under the Department of Pharmaceuticals, regulates drug prices under the Drugs (Prices Control) Order (DPCO), 2013, issued under the Essential Commodities Act, 1955. Its work gives substance to affordable healthcare as part of the right to life under Article 21 — a concern the Supreme Court underlined in September 2026 while terming cancer-drug overpricing a "broad daylight dacoity" [5].

Role in ensuring affordability

• Ceiling price fixation: NPPA fixes ceiling prices for "scheduled" drugs listed in Schedule I of DPCO 2013, drawn from the National List of Essential Medicines, which includes 63 anti-cancer drugs [1].
• Trade Margin Rationalisation (TMR): using extraordinary public-interest powers, NPPA capped trade margins at 30% on 42 non-scheduled anti-cancer medicines, cutting MRPs of 526 brands by about 50% on average and saving patients nearly ₹984 crore annually [2].
• Monitoring and enforcement: it caps annual price increases, recovers overcharged amounts, and complements fiscal steps such as customs-duty exemption and GST cuts on Trastuzumab, Osimertinib and Durvalumab [2].

Limitations

• List-based design: roughly 82% of medicines are non-scheduled, where launch prices are set freely — NPPA only restricts hikes beyond 10% a year [1].
• TMR is temporary: DPCO permits margin capping only as a time-bound, drug-by-drug order, not a standing power; the Standing Committee on Chemicals and Fertilisers (December 2025) therefore urged amending DPCO 2013 to make it permanent [3].
• Information gap: price-to-stockist data stays undisclosed, so the margin NPPA must police is invisible [3].
• Escape routes: fixed-dose combinations bypass price regulation, and stent prices still rose 29–44% between 2017 and 2024 despite control [3].
• Executive, not statutory status weakens its authority over non-scheduled formulations.

Affordability therefore needs both a stronger NPPA and higher public health spending — the route by which out-of-pocket expenditure already fell from 62.6% (2014-15) to 39.4% (2021-22) [4]. Amending DPCO to institutionalise trade-margin caps, mandating price-chain disclosure and closing the FDC loophole would convert episodic relief into durable access, advancing SDG-3 and Article 21.